Structure of aspartoacylase, the brain enzyme impaired in Canavan disease
- PMID: 17194761
- PMCID: PMC1766406
- DOI: 10.1073/pnas.0607817104
Structure of aspartoacylase, the brain enzyme impaired in Canavan disease
Abstract
Aspartoacylase catalyzes hydrolysis of N-acetyl-l-aspartate to aspartate and acetate in the vertebrate brain. Deficiency in this activity leads to spongiform degeneration of the white matter of the brain and is the established cause of Canavan disease, a fatal progressive leukodystrophy affecting young children. We present crystal structures of recombinant human and rat aspartoacylase refined to 2.8- and 1.8-A resolution, respectively. The structures revealed that the N-terminal domain of aspartoacylase adopts a protein fold similar to that of zinc-dependent hydrolases related to carboxypeptidases A. The catalytic site of aspartoacylase shows close structural similarity to those of carboxypeptidases despite only 10-13% sequence identity between these proteins. About 100 C-terminal residues of aspartoacylase form a globular domain with a two-stranded beta-sheet linker that wraps around the N-terminal domain. The long channel leading to the active site is formed by the interface of the N- and C-terminal domains. The C-terminal domain is positioned in a way that prevents productive binding of polypeptides in the active site. The structures revealed that residues 158-164 may undergo a conformational change that results in opening and partial closing of the channel entrance. We hypothesize that the catalytic mechanism of aspartoacylase is closely analogous to that of carboxypeptidases. We identify residues involved in zinc coordination, and propose which residues may be involved in substrate binding and catalysis. The structures also provide a structural framework necessary for understanding the deleterious effects of many missense mutations of human aspartoacylase.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Comment in
-
The impact of structural biology on neurobiology.Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):399-400. doi: 10.1073/pnas.0610164103. Epub 2007 Jan 3. Proc Natl Acad Sci U S A. 2007. PMID: 17213329 Free PMC article. No abstract available.
Similar articles
-
Mutational analysis of aspartoacylase: implications for Canavan disease.Brain Res. 2007 May 7;1148:1-14. doi: 10.1016/j.brainres.2007.02.069. Epub 2007 Mar 3. Brain Res. 2007. PMID: 17391648 Free PMC article.
-
Docking, molecular dynamics and free energy studies on aspartoacylase mutations involved in Canavan disease.J Mol Graph Model. 2017 Jun;74:44-53. doi: 10.1016/j.jmgm.2017.03.011. Epub 2017 Mar 19. J Mol Graph Model. 2017. PMID: 28349879
-
Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.FEBS Lett. 2006 Oct 30;580(25):5899-904. doi: 10.1016/j.febslet.2006.09.056. Epub 2006 Oct 2. FEBS Lett. 2006. PMID: 17027983
-
Canavan disease: a monogenic trait with complex genomic interaction.Mol Genet Metab. 2003 Sep-Oct;80(1-2):74-80. doi: 10.1016/j.ymgme.2003.08.015. Mol Genet Metab. 2003. PMID: 14567959 Review.
-
Canavan disease: diagnosis and molecular analysis.Genet Test. 1997;1(1):21-5. doi: 10.1089/gte.1997.1.21. Genet Test. 1997. PMID: 10464621 Review.
Cited by
-
Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.Metab Brain Dis. 2017 Dec;32(6):2105-2118. doi: 10.1007/s11011-017-0090-5. Epub 2017 Sep 6. Metab Brain Dis. 2017. PMID: 28879565
-
Multi-omic rejuvenation of human cells by maturation phase transient reprogramming.Elife. 2022 Apr 8;11:e71624. doi: 10.7554/eLife.71624. Elife. 2022. PMID: 35390271 Free PMC article.
-
N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells.J Biol Chem. 2013 Sep 6;288(36):26188-26200. doi: 10.1074/jbc.M113.487553. Epub 2013 Jul 24. J Biol Chem. 2013. PMID: 23884408 Free PMC article.
-
Temporal Alterations in White Matter in An App Knock-In Mouse Model of Alzheimer's Disease.eNeuro. 2024 Feb 26;11(2):ENEURO.0496-23.2024. doi: 10.1523/ENEURO.0496-23.2024. Print 2024 Feb. eNeuro. 2024. PMID: 38290851 Free PMC article.
-
Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.Hum Mutat. 2017 May;38(5):524-531. doi: 10.1002/humu.23181. Epub 2017 Feb 14. Hum Mutat. 2017. PMID: 28101991 Free PMC article.
References
-
- Baslow MH. Neurochem Res. 2003;28:941–953. - PubMed
-
- Clark JF, Doepke A, Filosa JA, Wardle RL, Lu A, Meeker TJ, Pyne-Geithman GJ. Med Hypotheses. 2006;67:506–512. - PubMed
-
- Tsai G, Coyle JT. Prog Neurobiol. 1995;46:531–540. - PubMed
-
- Gujar SK, Maheshwari S, Bjorkman-Burtscher I, Sundgren PC. J Neuroophthalmol. 2005;25:217–226. - PubMed
-
- Madhavarao CN, Chinopoulos C, Chandrasekaran K, Namboodiri MA. J Neurochem. 2003;86:824–835. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases